buy buy shorts TubeMogul reported a net gain attributable to common stockholders of a penny per diluted share, up from a loss 39 cents a share in the year-ago quarter. Revenue rose year-over-year to $28.72 million from $12.64 million. The consensus estimate called for a loss of 15 cents a share on revenue of $24.7 million.
this should be a great long term buy. The pipeline should be awesome and just what the different agencies need.
this is getting to a panic stage. This is getting to much attention for shorts. They have ran out of arguments.
Sovaldi) is a drug developed by Gilead Sciences used to treat hepatitis C infection. Always used In combination with other therapies, Sofosbuvir can effectively cure hepatitis in 90 percent of patients.... We went 12 for 12 and 100%
YA right idiot . Just when they go profitable with huge orders. The technology with the group are going mainstream now. I would cover as you are behind times. Times are changing.
Today they were all up again. Next week should be great. Gangsters calling them self streetsweaper tried to manipulate FCEL today. Searches came back as the site founder was charged with felonies in the past. Why would CNBC adds be on the site.